SMARCD1

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 · Q96GM5 · SMARCD1 on Sugi Atlas →

0 patent compounds predicted against SMARCD1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SMARCD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE2RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy PHASE2COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SMARCD1 binder may also engage these)

ProteinNameSimilarity
Q61466 1.000 Q61466 →
Q2TBN1 1.000 Q2TBN1 →
O54772 1.000 O54772 →
Q6P9Z1 1.000 Q6P9Z1 →
Q9VYG2 1.000 Q9VYG2 →
SMARCD2 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2 0.998 landscape →
Q6STE5 0.997 Q6STE5 →
E1BJD1 0.995 E1BJD1 →
Q99JR8 0.994 Q99JR8 →
Q09646 0.993 Q09646 →
O02101 0.988 O02101 →
Q9FMT4 0.987 Q9FMT4 →
Q7SH49 0.986 Q7SH49 →
Q960X8 0.985 Q960X8 →
Q17QQ4 0.984 Q17QQ4 →
Q2H401 0.984 Q2H401 →
Q9D7W5 0.984 Q9D7W5 →
Q96G25 0.984 Q96G25 →
Q6ZQ08 0.984 Q6ZQ08 →
Q5BGN5 0.984 Q5BGN5 →
P87253 0.984 P87253 →
Q8TC92 0.983 Q8TC92 →
Q5BKE0 0.983 Q5BKE0 →
Q60520 0.983 Q60520 →
P0C7N6 0.983 P0C7N6 →
TAF9 Transcription initiation factor TFIID subunit 9 0.983 landscape →
P53990 0.983 P53990 →
A0JP85 0.983 A0JP85 →
SIN3A Paired amphipathic helix protein Sin3a 0.983 landscape →
E3QDN5 0.983 E3QDN5 →